



## SHORT REPORT

## Effectiveness of electronic drug monitoring feedback to increase adherence in patients with RA initiating a biological DMARD: a randomised clinical trial

Renske CF Hebing <sup>1</sup>, Iremnur Aksu,<sup>2</sup> Jos WR Twisk,<sup>3</sup> Wouter Bos,<sup>4</sup> Bart Van den Bemt,<sup>5</sup> Michael T Nurmohamed <sup>6</sup>

**To cite:** Hebing RCF, Aksu I, Twisk JWR, *et al.* Effectiveness of electronic drug monitoring feedback to increase adherence in patients with RA initiating a biological DMARD: a randomised clinical trial. *RMD Open* 2022;**8**:e001712. doi:10.1136/rmdopen-2021-001712

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/rmdopen-2021-001712>).

ACR Convergence 2020

Received 26 April 2021

Accepted 14 September 2021



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

**Correspondence to**

Ms Renske CF Hebing, Reade, Amsterdam, Netherlands; [r.hebing@reade.nl](mailto:r.hebing@reade.nl)

**ABSTRACT**

**Objective** Medication non-adherence in rheumatoid arthritis (RA) is associated with disease flares, increased disability and increased costs. This study assessed the effectiveness of electronic monitoring feedback (EMF) on medication adherence in patients with RA starting with or switching to a new biological disease-modifying antirheumatic drug (bDMARD).

**Methods** In this randomised controlled trial, bDMARD starters were assigned to the intervention or control group and followed for 1 year. The intervention group received a needle container with a Medication Event Monitoring System (MEMS) cap registering patient's adherence to injections. Scores were calculated every 3 months with MEMS and motivational interviewing feedback was given. The control group received usual care. Effectiveness of EMF on adherence was measured with the medication possession ratio (MPR).

**Results** 104 consecutive intervention patients were included and 102 controls. MPR was 0.95 (SD: 0.10) and 0.90 (0.16) after 12 months (B: 0.036, 95% CI: 0.001 to 0.007,  $p=0.045$ ). bDMARD-naïve patients receiving EMF achieved low disease activity (LDA) sooner compared with the control group, adjusted for baseline DAS (HR: 1.68, 95% CI: 1.00 to 2.81,  $p=0.050$ ). Side effects and DAS28 were similar.

**Conclusion** EMF increased adherence for patients with RA starting with or switching to a bDMARD. Especially bDMARD-naïve patients achieved LDA sooner compared with the control group, which holds promise for the future.

**INTRODUCTION**

Effectiveness of pharmacotherapy can be limited by inadequate medication adherence, defined as the degree to which the person's behaviour corresponds with the agreed recommendations from a healthcare provider.<sup>1</sup> In rheumatoid arthritis (RA), it is estimated that 4%–37% of the patients are non-adherent to medication, depending on

**Key messages****What is already known about this subject?**

- Medication non-adherence occurs frequently in patients with rheumatoid arthritis (RA) and decreases treatment outcomes. Effective interventions to improve adherence are absent.

**What does this study add?**

- Electronic monitoring feedback (EMF) improves medication adherence in patients with RA starting with or switching to a new biological disease-modifying antirheumatic drugs, as measured with the medication possession ratio.

**How might this impact on clinical practice or further developments?**

- EMF might be applied in usual care to improve medication adherence. In order to have maximum clinical effect, it is advisable for future research to focus on the most suitable subgroup of patients with RA.

the duration of disease and/or study, method of measurement and medication.<sup>2–8</sup> Non-adherence is associated with disease flares, radiological damage and increased disability and increased costs.<sup>9 10</sup> Therefore, increasing medication adherence is essential for both patients and society.

In a systematic review, electronic monitoring feedback (EMF) as an intervention to improve adherence showed promising results. However, the included studies had several limitations, such as inadequate sample sizes, too short follow-up and not specific for RA.<sup>8 11</sup> To address these limitations, we developed a study based on EMF to encourage dialogue between patients and healthcare professionals regarding concerns about

medication, practical barriers and necessity of regular medication intake.

The primary objective was to examine the effectiveness of the electronic drug monitoring adherence feedback on medication adherence, in standard care for patients with RA starting with or switching to a new biological disease-modifying antirheumatic drug (bDMARD).

The secondary objectives of this study were to study the effect of the intervention on time to low disease activity (DAS28 ESR 2.6–3.2) and remission (DAS28 ESR <2.6), proportion of patients with low disease activity/remission and proportion of switching patients to another bDMARD, side effects and mean disease activity after 1 year.

## METHODS

In this open randomised clinical trial, consecutive adult patients with a clinical diagnosis of RA (2010 ACR classification criteria) were included in Reade, Amsterdam, The Netherlands, between December 2015 and July 2019 (protocol in online supplemental file 2). Patients starting with or switching to a (new) subcutaneously administered bDMARD were invited. Patients were randomly assigned 1:1 to the experimental or control condition using a computer-generated randomisation list (blocks of 8). This study was conducted regarding the ethical principles for medical research as stated in the Declaration of Helsinki and reported according to the CONSORT guidelines. The Medical Ethics Committee of Reade and Slotervaart approved this study. Patients and public were involved in the design of a prior study, which was the basis for this study.<sup>12</sup>

## Interventions

Patients in the intervention group received a special needle disposal container which was equipped with a Medication Event Monitoring System cap (MEMS and MEMS Adherence Software, AARDEX Group).<sup>13</sup>

Adherence was read out every 3 months and motivational interviewing (MIT)-based feedback was given by pharmacists and pharmacy technicians. In case of valid medical reasons (eg, infections or surgery) to miss one or several doses, a non-monitored period was added in the digital MEMS platform. If non-adherence was measured, possible barriers to medication intake were counselled. Communication about non-adherence was facilitated with a communication (semi structured) model developed by Linn *et al* (online supplemental material).<sup>14</sup>

Pharmacists and pharmacy technicians received a communication training by Linn based on the practical and perceptual barriers typology.<sup>14</sup> Pharmacists gave feedback regularly on the communication of the pharmacy technicians, assuring correct EMF.

Patients in the control group received standard care.

## Outcome

The primary outcome measure was the difference in the medication possession ratio (MPR) in the feedback group

compared with usual care after 12 months MPR is the ratio of the number of days with ‘coverage’ of bDMARDs in a defined period, divided by the total number of days in that period ( $\geq 80\%$  is adherent). We corrected for temporal discontinuation because of contra-indications and for syringe defects and returns.

Secondary outcome measures were the Compliance Questionnaire in Rheumatology (CQR) at 12 months, DAS28, proportion of switchers, time to at least LDA and remission and side effects. We used the discriminant CQR  $Z_k$  score.<sup>15</sup> This cutting score for taking compliance was used, since it was validated with the MPR. Three or less ‘missings’ were imputed according to Zwicker *et al*.<sup>16</sup>

Patient’s DAS28-ESR was assessed approximately every 3 months, by a physician or a nurse. Time to LDA and remission were calculated, from 3 ( $\pm 1$  month) months onwards, corresponding to the first moment of feedback in the intervention group. Total number of patients in remission or LDA was noted, as well as the use of comedication (other DMARD’s, corticosteroids). We obtained documented side effects.

## Sample size

The target sample size was computed using Stata to provide 80% power to detect a 18% difference in adherence between an expected 83% adherence rate in the intervention group after 1 year versus 65% in the usual care arm, using a significance level of 0.05.<sup>7 17</sup> The required sample size would be 206 (103 patients per arm), taking into account a 10% non-inclusion and/or loss to follow-up.

## Statistical methods

Descriptive statistics were used for demographic data, using means ( $\pm$ SD), medians (IQR) or percentages, based on intention-to-treat.

Linear regression analysis was used to evaluate differences in MPR (dependent) between intervention and control patients (primary outcome). Logistic regression analyses were used for proportions of adherent patients and other binary outcomes. Differences in DAS28 scores (dependent) over time between intervention and control patients were analysed with linear mixed-model analysis. To analyse whether there is a difference in time to achievement of low disease activity and/or time to the next bDMARD, cox proportional hazards analysis was used to generate HRs and a 95% CI. Between-group differences were visualised by Kaplan-Meier time-to-event curves. In all (regression) analyses possible confounders (ie, independent variables baseline DAS28-ESR, age, gender, disease duration and bDMARD use before) were selected with a forward procedure (final selection criterion  $>10\%$  change in effect estimate).

**Table 1** Baseline characteristics

	Baseline	
	Feedback (n=104)	Control (n=102)
Female gender, (%)	73 (70)	74 (73)
Age, years (SD)	53.5 (12.1)	51.2 (13.6)
BMI, kg/m <sup>2</sup> (SD)	26.1 (5.9)	25.9 (4.8)
Ethnicity, Caucasian (%)	90 (87)	85 (83)
Disease duration (years, SD)	6.3 (7.07)	5.7 (5.85)
DAS28-ESR, (SD)	4.0 (1.4)	3.8 (1.5)
DAS28-ESR, (%)		
▶ Remission (<2.6)	16 (15.2)	21 (20.6)
▶ Low (≥2.6 and <3.2)	12 (11.4)	8 (7.8)
▶ Moderate (≥3.2 and ≤5.1)	42 (40.0)	41 (40.2)
▶ High (>5.1)	27 (25.7)	22 (21.6)
HAQ (SD)	1.13 (0.7)	0.98 (0.6)
Concomitant medications, (%)		
▶ Methotrexate	64 (61)	56 (55)
▶ Prednisolone or triamcinolone	36 (35)	41 (40)
▶ Other csDMARD(s)	30 (29)	39 (38)
▶ Triamcinolone acetonide injection (intramuscular) (%)	4 (3.8)	3 (2.9)

Number of patients and means are presented, unless otherwise stated.

BMI, body mass index; csDMARD, conventional disease modifying antirheumatic drug; DAS28, Disease Activity Score for 28 joints; ESR, Erythrocyte sedimentation rate.

## RESULTS

A total of 206 consecutive patients were included (table 1). Most patients started with etanercept or adalimumab. In both groups, 76% of the patients started a first bDMARD.

Table 2 displays the most important findings. Patients in the intervention group had higher adherence levels as measured by MPR, but proportions of adherent patients did not differ. Mean DAS28-ESR was 2.90 (SD: 1.5) and

2.79 (1.3) at month 3 for interventions and controls, respectively, 2.71 (1.4) and 2.71 (1.3) at month 6, 2.50 (1.5) and 2.48 (1.3) at month 9 and 2.58 (1.3) and 2.74 (1.6) at month 12 (no differences at all time points). Overall, the intervention did not result in improvement of disease activity (0.504,  $p=0.260$ , 95% CI: -0.38 to 1.39).

Adverse effects (AEs) such as injection side reactions and respiratory complaints were reported by 49 (47%) intervention patients and 58 (57%) controls ( $\chi^2$ : 2.154,  $p=0.142$ ). No serious AEs were reported. In total, 42% ceased their bDMARD, because of side effects, loss of effect or other reasons (similar for both groups). The proportion of switchers to another bDMARD was alike.

The median time to achieve LDA (after 3 months or the first feedback) was 4.34 months in the intervention group versus 4.14 months in the control group. The median time to achieve remission was 6.57 months in the intervention group versus 6.44 months in the control group. In the final multivariable model for time to LDA (adjusted for baseline DAS28-ESR), HR was 1.29 ( $p=0.26$ , 95% CI: 0.83 to 2.01). For time to remission (adjusted for baseline DAS28-ESR, gender and BMI), HR was 1.21 ( $p=0.45$ , 95% CI: 0.74 to 1.96).

In the biological-naïve subgroup, the HR adjusted for baseline DAS28-ESR was 1.68 for time to LDA for the intervention group compared with the control group ( $p=0.050$ , 95% CI: 1.00 to 2.81, figure 1). HR for time to remission was 1.52, adjusted for gender and baseline DAS28-ESR ( $p=0.141$ , 95% CI: 0.87 to 2.65, online supplemental figure S2). For switchers the dissimilarities were not statistically different.

## DISCUSSION


We found a favourable effect of electronic drug monitoring adherence feedback on MPR. Furthermore, bDMARD-naïve patients in the intervention group achieved LDA slightly sooner compared with controls. No effect was found on proportion of adherent patients based on CQR, proportion of patients ceasing their

**Table 2** Adherence and disease activity outcomes at 12 months

	Intervention	Control	Crude effect estimate (p, 95% CI)	Corrected effect estimate (p, 95% CI)
Primary outcome				
MPR (SD)	0.95 (0.10)	0.90 (0.16)	B: 0.051 (0.009, 0.088 to -0.013)	B: 0.036 (0.045, 0.001 to 0.071)*
Proportion adherent, MPR ≥0.8	92	85	OR 1.63 (0.121, 1.22 to 3.35)	OR 1.83 (0.319, 1.14 to 5.10)*
Secondary outcomes				
Proportion adherent, CQR Z <sub>k</sub> score	67	75	OR: 2.01 (0.373, 1.37 to 4.67)	NA
Proportion LDA	75	80	OR: 2.05 (0.352, 1.43 to 4.22)	NA
Proportion remission	56	68	OR: 1.83 (0.101, 1.39 to 3.01)	NA

\*Means and (SD) or proportions are displayed. We corrected for baseline DAS28.

CQR, Compliance Questionnaire in Rheumatology; LDA, Low disease activity; MPR, medication possession ratio.



**Figure 1** Kaplan-Meier plot of the cumulative probability of achieving at least LDA for biological-naïve patients in the intervention (red) and control group (blue). Each step in the curve represents at least LDA, defined as DAS28-ESR <3.2. — control, — intervention, + control-censored, + intervention-censored.

bDMARD, number of patients reporting side effects, use of co-medication and mean disease activity after 1 year.

An overview of systematic reviews of adherence in patients with RA underscores that non-adherence is complex and a golden standard is non-existent.<sup>18</sup> Educational or behavioural interventions, of which multicomponent, tailored and motivational strategies, show the best results. In our study, we confirmed the effect of these strategies by EMF.

Our intervention EMF comprises, among others, MIT, a strategy that has been proven to improve adherence.<sup>11</sup> This might have affected adherence most, although this cannot formally be attributed to one particular aspect of EMF.

Adherence in these patients with RA was relatively high, as measured with MPR and MEMS (only intervention group, online supplemental figure S3), compared with other methods and other chronic diseases.<sup>11</sup> This might be partially due to the Hawthorn effect, although that this was not expected in the control group.<sup>16</sup> Furthermore, our high adherence rates correspond with other studies, since we have also corrected for periods of infections and other legitimate reasons for temporarily discontinuation.<sup>3 18</sup>

Although van Heuckelum *et al* in their review suggested a favourable effect of EMF on clinical outcomes in some studies we did not find this. This might be due to selection bias, adequate usual care according to the treat to target paradigm and a too small sample size to detect the limited difference in adherence rates between groups. However, we did see a small effect on time to LDA for bDMARD-naïve patients, making this group a target for further research.

EMF increased adherence for patients with RA starting with or switching to a bDMARD. Especially bDMARD-naïve patients benefitted most, since they achieved LDA

slightly sooner compared with the control group, which holds promise for the future.

#### Author affiliations

<sup>1</sup>Rheumatology, Pharmacy, Reade Hoofdlocatie Dr Jan van Breemenstraat, Amsterdam, The Netherlands

<sup>2</sup>Reade Hoofdlocatie Dr Jan van Breemenstraat, Amsterdam, The Netherlands

<sup>3</sup>Department of Methodology and Applied Biostatistics, Amsterdam UMC Locatie VUmc, Amsterdam, The Netherlands

<sup>4</sup>Rheumatology, Reade Hoofdlocatie Dr Jan van Breemenstraat, Amsterdam, The Netherlands

<sup>5</sup>Pharmacy, Sint Maartenskliniek Afdeling Reumatologie, Nijmegen, The Netherlands

<sup>6</sup>Rheumatology and Internal Medicine, Reade Hoofdlocatie Dr Jan van Breemenstraat, Amsterdam, The Netherlands

**Acknowledgements** We thank all participating patients. We also thank Maaïke Heslinga and Eva Kneepkens for helping designing the study and all pharmacy technicians for their assistance.

**Contributors** MTN and BvdB designed the study and obtained the grant, RCFH coordinated the study, collected the data and drafted the manuscript. All authors participated in designing the analyses, interpreting the results and revision and approval of the (final) manuscript. BvdB and MTN are shared last authors.

**Funding** Pfizer provided a grant for this study (53232353/WI193646).

**Competing interests** None declared.

**Patient and public involvement statement** Patients and public were involved in the design of a prior study, which was the basis for this study (van Heuckelum 2019)

**Patient consent for publication** Consent obtained directly from patient(s).

**Ethics approval** The Medical Ethics Committee of Reade and Slotervaart approved this study: NL 51522.048.14.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

#### ORCID iDs

Renske CF Hebing <http://orcid.org/0000-0002-6725-6719>

Michael T Nurmohamed <http://orcid.org/0000-0002-6274-1934>

#### REFERENCES

- Dobbels F, Van Damme-Lombaert R, Vanhaecke J, *et al*. Growing pains: non-adherence with the immunosuppressive regimen in adolescent transplant recipients. *Pediatr Transplant* 2005;9:381–90.
- Calvo-Alén J, Monteagudo I, Salvador G, *et al*. Non-adherence to subcutaneous biological medication in patients with rheumatoid arthritis: a multicentre, non-interventional study. *Clin Exp Rheumatol* 2017;35:423–30.
- Vogelzang EH, Hebing RCF, Nurmohamed MT, *et al*. Adherence to etanercept therapy in rheumatoid arthritis patients during 3 years of follow-up. *PLoS One* 2018;13:e0205125.
- van den Bemt BJJ, Zwicker HE, van den Ende CHM. Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. *Expert Rev Clin Immunol* 2012;8:337–51.
- Koncz T, Pentek M, Brodsky V, *et al*. Adherence to biologic DMARD therapies in rheumatoid arthritis. *Expert Opin Biol Ther* 2010;10:1367–78.
- Curtis JR, Bykerk VP, Aassi M, *et al*. Adherence and persistence with methotrexate in rheumatoid arthritis: a systematic review. *J Rheumatol* 2016;43:1997–2009.
- van den Bemt BJJ, van den Hoogen FHJ, Benraad B, *et al*. Adherence rates and associations with nonadherence in patients with rheumatoid arthritis using disease modifying antirheumatic drugs. *J Rheumatol* 2009;36:2164–70.
- Seewoodharry MD, Maconachie GDE, Gillies CL, *et al*. The effects of feedback on adherence to treatment: a systematic review and meta-analysis of RCTs. *Am J Prev Med* 2017;53:232–40.

- 9 Dalén J, Svedbom A, Black CM, *et al.* Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence. *Rheumatol Int* 2016;36:987–95.
- 10 Contreras-Yáñez I, Ponce De León S, Cabiedes J, *et al.* Inadequate therapy behavior is associated to disease flares in patients with rheumatoid arthritis who have achieved remission with disease-modifying antirheumatic drugs. *Am J Med Sci* 2010;340:282–90.
- 11 van Heuckelum M, van den Ende CHM, Houterman AEJ, *et al.* The effect of electronic monitoring feedback on medication adherence and clinical outcomes: a systematic review. *PLoS One* 2017;12:e0185453.
- 12 van Heuckelum M, Linn AJ, Vandeberg L, *et al.* Implicit and explicit attitudes towards disease-modifying antirheumatic drugs as possible target for improving medication adherence. *PLoS One* 2019;14:e0221290.
- 13 de Klerk E, van der Heijde D, Landewé R, *et al.* Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. *J Rheumatol* 2003;30:44–54.
- 14 Linn AJ, van Weert JC, Schouten BC, *et al.* Words that make pills easier to swallow: a communication typology to address practical and perceptual barriers to medication intake behavior. *Patient Prefer Adherence* 2012;6:871–85.
- 15 de Klerk E, van der Heijde D, Landewé R, *et al.* The compliance-questionnaire-rheumatology compared with electronic medication event monitoring: a validation study. *J Rheumatol* 2003;30:2469–75.
- 16 Zwikker HE, van Dulmen S, den Broeder AA, *et al.* Perceived need to take medication is associated with medication non-adherence in patients with rheumatoid arthritis. *Patient Prefer Adherence* 2014;8:1635–45.
- 17 Egsmose C, Lund B, Borg G, *et al.* Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. *J Rheumatol* 1995;22:2208–13.
- 18 Ritschl V, Stamm TA, Aletaha D, *et al.* 2020 EULAR points to consider for the prevention, screening, assessment and management of non-adherence to treatment in people with rheumatic and musculoskeletal diseases for use in clinical practice. *Ann Rheum Dis* 2020. doi:10.1136/annrheumdis-2020-218986. [Epub ahead of print: 18 Dec 2020].